Biomarkers /
MAD1L1
Back to Biomarkers List
Associated Diseases
Overview
MAD1L1 is altered in 0.07% of all cancers with low-grade glioma, NOS, pancreatic adenocarcinoma, pilocytic astrocytoma, thyroid gland papillary carcinoma, and astrocytoma having the greatest prevalence of alterations [3].
The most common alterations in MAD1L1 are MAD1L1-BRAF Fusion (0.06%), MAD1L1-ALK Fusion (0.09%), MAD1L1-CDKN1B Fusion (0.02%), and MAD1L1-RAF1 Fusion (0.02%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.